Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 6/2014

01-08-2014 | Research Paper

ADRM1 gene amplification is a candidate driver for metastatic gastric cancers

Authors: Seok Hoon Jang, Jun Won Park, Hyo Rim Kim, Je Kyung Seong, Hark Kyun Kim

Published in: Clinical & Experimental Metastasis | Issue 6/2014

Login to get access

Abstract

We searched for candidate target genes in metastatic gastric cancer, using comparative genomic hybridization (CGH) and mRNA expression array analysis of endoscopic biopsy samples collected from 32 patients. Recurrent amplicons included 17q21.2 (36,569,293–37,307,055), 8q24.13-q24.21 (126,357,475–130,159,285), and 20q13.33 (60,211,249–61,382,787). In this paper, we focused on the 1.1-Mb genomic region containing 24 genes in chromosome 20q13.33 (from 60,211,249 to 61,382,787), the third most frequent amplicon that was amplified in three of 32 patients (9.4 %), with log2 tumor/reference ratios ranging from 0.6 to 1.5. Of three genes in the 20q13.33 amplicon, ADRM1 was chosen for functional analyses. ADRM1 knockdown suppressed the proliferation of two human gastric cancer cells, SNU-601 and SNU-216. Overexpression of Adrm1 promoted cell proliferation of conditionally-immortalized, mouse ImSt gastric epithelial cells, with increased S1 phase fraction and decreased expression of p21(Cip1). These results collectively indicate that ADRM1 promoted gastric epithelial cell proliferation by cell cycle progression. Therefore, ADRM1 is a candidate target gene in the chromosome 20q13.33 amplicon that may possibly be linked to development of gastric cancer.
Appendix
Available only for authorised users
Literature
1.
Alberts S, Cervantes A, van de Velde C (2003) Gastric cancer: epidemiology, pathology, and treatment. Ann Oncol 14(Suppl 2):ii31–ii36PubMed
2.
Kim HK, Green JE (2014) Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents. Pharmacogenomics 15(3):375–384PubMedCrossRef
3.
Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Yamada Y, Arao T, Nishio K, Michalowski A, Green JE (2012) Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. Pharmacogenomics J 12(2):119–127PubMedCentralPubMedCrossRef
4.
Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A, Green JE (2011) A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS ONE 6(2):e16694PubMedCentralPubMedCrossRef
5.
Cheng L, Wang P, Yang S, Yang Y, Zhang Q, Zhang W, Xiao H, Gao H, Zhang Q (2012) Identification of genes with a correlation between copy number and expression in gastric cancer. BMC Med Genomics 5:14PubMedCentralPubMedCrossRef
6.
Fan B, Dachrut S, Coral H, Yuen ST, Chu KM, Law S, Zhang L, Ji J, Leung SY, Chen X (2012) Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer. PLoS ONE 7(4):e29824
7.
Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R, Ke XS, Oyan AM, Kalland KH, Rotter V, Domany E (2011) Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS ONE 6(1):e14632PubMedCentralPubMedCrossRef
8.
Husnjak K, Elsasser S, Zhang N, Chen X, Randles L, Shi Y, Hofmann K, Walters KJ, Finley D, Dikic I (2008) Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 453(7194):481–488PubMedCentralPubMedCrossRef
9.
Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, Karlan B, Slamon DJ (2008) Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target. Genes Chromosomes Cancer 47(10):873–883PubMedCrossRef
10.
Chen W, Hu XT, Shi QL, Zhang FB, He C (2009) Knockdown of the novel proteasome subunit Adrm1 located on the 20q13 amplicon inhibits colorectal cancer cell migration, survival and tumorigenicity. Oncol Rep 21(2):531–537PubMed
11.
Yan F, Cao H, Chaturvedi R, Krishna U, Hobbs SS, Dempsey PJ, Peek RM Jr, Cover TL, Washington MK, Wilson KT, Polk DB (2009) Epidermal growth factor receptor activation protects gastric epithelial cells from Helicobacter pylori-induced apoptosis. Gastroenterology 136(4):1297–1307PubMedCentralPubMedCrossRef
12.
Schreiner P, Chen X, Husnjak K, Randles L, Zhang N, Elsasser S, Finley D, Dikic I, Walters KJ, Groll M (2008) Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction. Nature 453(7194):548–552PubMedCentralPubMedCrossRef
13.
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A (2003) UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res 63(14):4167–4173PubMed
14.
Yao T, Song L, Xu W, DeMartino GN, Florens L, Swanson SK, Washburn MP, Conaway RC, Conaway JW, Cohen RE (2006) Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat Cell Biol 8(9):994–1002PubMed
15.
Hamazaki J, Iemura S, Natsume T, Yashiroda H, Tanaka K, Murata S (2006) A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes. EMBO J 25(19):4524–4536PubMedCentralPubMedCrossRef
16.
Qiu XB, Ouyang SY, Li CJ, Miao S, Wang L, Goldberg AL (2006) hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37. EMBO J 25(24):5742–5753PubMedCentralPubMedCrossRef
17.
Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, Zeng Z, Liu H, Krier C, Stengel RF, Barany F, Gerald WL, Paty PB, Domany E, Notterman DA (2006) Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res 66:2129–2137PubMedCrossRef
18.
Hodgson JG, Chin K, Collins C, Gray JW (2003) Genome amplification of chromosome 20 in breast cancer. Breast Cancer Res Treat 78:337–345PubMedCrossRef
19.
Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC, van Der Kwast TT, Schröder FH, Tanke HJ, van Dekken H (2001) Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am J Pathol 158:399–406PubMedCentralPubMedCrossRef
20.
Mahlamaki EH, Barlund M, Tanner M, Gorunova L, Hoglund M, Karhu R, Kallioniemi A (2002) Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 35:353–358PubMedCrossRef
21.
Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, Hung CF, Chen X, Walters KJ, Roden RB (2013) A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell 24(6):791–805PubMedCrossRef
Metadata
Title
ADRM1 gene amplification is a candidate driver for metastatic gastric cancers
Authors
Seok Hoon Jang
Jun Won Park
Hyo Rim Kim
Je Kyung Seong
Hark Kyun Kim
Publication date
01-08-2014
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 6/2014
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-014-9663-4

Other articles of this Issue 6/2014

Clinical & Experimental Metastasis 6/2014 Go to the issue

Research Paper

Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors

Research Paper

COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib

Research Paper

Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells

Research Paper

High expression of S100A4 and endoglin is associated with metastatic disease in head and neck squamous cell carcinoma

Research Paper

Living in shear: platelets protect cancer cells from shear induced damage

Research Paper

Metadherin expression and lung relapse in patients with colorectal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits